Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Lung Cancer》 2009-06
Add to Favorite Get Latest Update

Analysis of Cardiovascular-related Adverse Effects of Endostar Combined with Chemotherapy in 61 NSCLC Cases

Wenjing MENG, Qi GAO, Liuchun WANG, Chun HUANG, Kai LIDepartment of Pulmonary Oncology, Tianjin Medical University Tumor Institute and Hospital, Tianjin Lung Cancer Diagnosis and Treatment Centre, Tianjin 300060, China  
Background and objective Anti-angiogenesis is one of the e ective methods of the treatment of ma-lignancies. The result of the clinical trial of anti-angiogenic drugs which approved by US Food and Drug Administration(FDA) suggest that the effect is amazing, but the adverse effects must be valued, especially the cardiovascular system-related adverse effects. The objective of this study is to analyze factors impacting cardiovascular-related adverse effects of endostar with chemo-therapy. Methods 61 cases of advanced non-small cell lung cancer treated by endostar with chemotherapy from April 2007 to February 2009 were enrolled into retrospective analysis. During the treatment, blood pressure, electrocardiogram(ECG) and D-Dimer were monitored at designed points. The symptoms such as headache, palpitation, dizziness were also observed. Results Frequency of adverse effects ranks as abnormal ECG, abnormal D-Dimer, abnormal platelet, clinical symptoms and abnormal blood pressure. Basing on the case cycle observations, between pre-treatment and post-treatment, significant correlation was found among the ECG changes, clinical syndrome and blood pressure fluctuations(P0.05). Logistic regression analysis of single-factor exhibits ST-T changes and fluctuations in blood pressure were related to age on cycles observation (P0.05), fluctuation in blood pressure were related to the chemotherapy cycles (P0.05). However, Logistic regression analysis of multi-factor revealed ST-T changes and blood pressure fluctuation were related to age on cycles observation (P0.05). Conclusion In this observation, the frequency of abnormal ECG is the most common event. Age could affect the frequency of abnormal change of ECG and blood pressure fluctuation. Transitory abnormal change of ECG and blood pressure fluctuation tend to be represented in older patients. The patients with existed cardiovascular illness history are likely to undergo abnormal change of ECG when treated with those drugs for a long term. Compared to young patients, the olders are more susceptible to suffer fromabnormal changes of ECG, blood pressure fluctuations and the obvious symptom. The number of treatment cycles could affect blood pressure uctuations. Above adverse e ects are recoverable in the end of therapy.
【Fund】: 吴阶平基金会临床科研专项基金(04101002)
【CateGory Index】: R734.2
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【References】
Chinese Journal Full-text Database 1 Hits
1 LIU Xiu-feng,QIN Shu-kui.Cancer Center of PLA,81 Hospital of PLA,Nanjing 210002,China;Current progression of endostar on clinical application and research[J];Chinese Clinical Oncology;2009-10
【Citations】
Chinese Journal Full-text Database 4 Hits
1 SHI Heling, XU Liyan, LIU Zhe. Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Hospital, Beijing 101149, P.R.China;Phase Ⅱ clinical trial of homemade human rh-endostatin in the treatment of patients with stage ⅢB--Ⅳ non-small cell lung cancer[J];Chinese Journal of Lung Cancer;2004-04
2 WANG Jinwan, SUN Yan, LIU Yongyu, YU Qitao, ZHANG Yiping, LI Kai, ZHU Yunzhong, ZHOU Qinghua, HOU Mei, GUAN Zhongzhen, LI Weilian, ZHUANG Wu, WANG Donglin, LIANG Houjie, QIN Fengzhan, LU Huishan, LIU Xiaoqing, SUN Hong, ZHANG Yanjun, WANG Jiejun, LUO Suxia, YANG Ruihe, TU Yuanrong, WANG Xiuwen, SONG Shuping, ZHOU Jingmin, YOU Lifen, WANG Jing, YAO Chen.  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, P.R.China;Results of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients[J];Chinese Journal of Lung Cancer;2005-04
3 QIN Jing1, ZHANG Penghai1, QIAN Xinyu1, LI Aimin1, LUO Rongcheng1, XU Dingli2 1Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 501516, China 2Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 501516, China;Analysis of Cardiotoxicity of Recombinant Human Endostatin Combined with Chemotherapy[J];Chinese Journal of Clinical Oncology;2008-01
4 LIU Yong-yu;Phase Ⅲ Clinical Trial of Recombinant Human Endostatin in the Treatment for Advanced Non-small Cell Lung Cancer Patients[J];Bulletin of Chinese Cancer;2005-06
【Co-citations】
Chinese Journal Full-text Database 10 Hits
1 Anhui Provincial Construction Hospital,Hefei 230022,AnhuiXU Li-ping;Nursing and Observation of 10 Cases of Advanced Stage Tumor Patients Treated with Endostar[J];Journal of Anhui Health Vocational & Technical College;2008-06
2 Li Yong Zhang Xiangru Sun Yan Cancer Institute & Hospital,CAMS & PUMC,Beijing 100021,China;Advances of targeted therapy in the treatment of non-small cell lung cancer[J];Oncology Progress;2007-02
3 Yuan Xia~1 Zhang Dongsheng~1 Yuan Zhongyu~1 He Ying~2 Ma Huimin~2 Li Jun~2 Jiang Wenqi~(1#) 1 State Key Laboratory of Oncology in South China,Department of Medical Oncology,Cancer Center,Sun Yat-sen University,Guangzhou,Guangdong,510060,P.R.China 2 Huizhou Municipal Center Hospital,Huizhou,Guangdnng,516001,P.R.China;Endostar combined with chemotherapy in the treatment of HER-2 negative breast cancer[J];Oncology Progress;2007-06
4 Li Yong Sun Yan Zhang Xiangru Cancer Institute & Hospital,CAMS&PUMC,Beijing 100021,China;The andvances of tumor anti-angiogenetic therapy[J];Oncology Progress;2008-01
5 Li Lixia~# Zheng Jihua Zhang Weimin Department of Oncology,Guangzhou General Hospital of PLA,Guangzhou 510010,China;Clinical application of recombinant human endostatin[J];Oncology Progress;2009-02
6 JIANG Kui,SUN Xiu-hua,YANG Xiao-yan,ZHANG Xian,ZHANG Yang(Department of Oncology,the Second Affiliated Hospital of Dalian Medical University,Dalian 116027,China);Vinorelbine and cisplatin regimein in treating elder patients with advanced non-small cell lung cancer[J];Journal of Dalian Medical University;2008-01
7 QIN Jing1, ZHANG Peng-hai1, QIAN Xin-yu1, KANG Shi-jun1, LUO Rong-cheng1, Wang Yue-gang2 1Department of Oncology, 2Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China;Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients[J];Journal of Southern Medical University;2008-06
8 SUN Yan, LIN Hongsheng, ZHU Yunzhong, FENG Jifeng, CHEN Zhengtang, LI Gongshu, ZHANG Xiangru, ZHANG Zongqi, TANG Junfang, SHI Meiqi, HAO Xuezhi, HAN Hui. *Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences & PUMC, Beijing 100021, P.R.China;A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients[J];Chinese Journal of Lung Cancer;2006-03
9 Qinghua ZHOU Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China;New Year Wishes[J];Chinese Journal of Lung Cancer;2009-01
10 Haiyu MU,Chunyan SHEN,Yiling FENG Cancer center,The affiliated hospitalof Armed Police for Medical College,Tianjin 300162,China;Clinical Observation on the Target Therapy of Rh-Endostin,Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer[J];Chinese Journal of Lung Cancer;2009-07
China Proceedings of conference Full-text Database 2 Hits
1 ;Five reports on treatingⅢstage of NSCLC with En-du and Kang-lai-te inject[A];[C];2007
2 PAN Yan (Department of Pharmacy,Shanghai Chest Hospital,200030);Development in clinical research of Endostar for malignant tumor[A];[C];2009
【Co-references】
Chinese Journal Full-text Database 10 Hits
1 Yuan Xia~1 Zhang Dongsheng~1 Yuan Zhongyu~1 He Ying~2 Ma Huimin~2 Li Jun~2 Jiang Wenqi~(1#) 1 State Key Laboratory of Oncology in South China,Department of Medical Oncology,Cancer Center,Sun Yat-sen University,Guangzhou,Guangdong,510060,P.R.China 2 Huizhou Municipal Center Hospital,Huizhou,Guangdnng,516001,P.R.China;Endostar combined with chemotherapy in the treatment of HER-2 negative breast cancer[J];Oncology Progress;2007-06
2 DENG Li1,ZHANG Xuan-zhen2,WANG Wei-dong1,CHEN Zheng-tang1,CAO Zheng-huai1(1Cancer Research Center,Xinqiao Hospital,Third Military Medical University,Chongqing 400037;2Department of Pathology,Women's and Children's Health Care Hospital of Chongqing,Chongqing 400013,China);Recombinant human endostatin combined with paclitaxel-cisplatin chemotherapy in treatment of human breast cancer xenograft in nude mice[J];Acta Academiae Medicinae Militaris Tertiae;2008-09
3 WANG Jinwan, SUN Yan, LIU Yongyu, YU Qitao, ZHANG Yiping, LI Kai, ZHU Yunzhong, ZHOU Qinghua, HOU Mei, GUAN Zhongzhen, LI Weilian, ZHUANG Wu, WANG Donglin, LIANG Houjie, QIN Fengzhan, LU Huishan, LIU Xiaoqing, SUN Hong, ZHANG Yanjun, WANG Jiejun, LUO Suxia, YANG Ruihe, TU Yuanrong, WANG Xiuwen, SONG Shuping, ZHOU Jingmin, YOU Lifen, WANG Jing, YAO Chen.  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, P.R.China;Results of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients[J];Chinese Journal of Lung Cancer;2005-04
4 XU Hairong, TIAN Wei, NIU Xiaohui, et al. The Fourth Clinical Medicine College, Peking University, Beijing, 100035, China;In vitro study of recombinant human endostatin in combination with adriamycin on human osteosarcoma cell OS-732[J];Chinese Journal of Bone Tumor and Bone Disease;2008-03
5 HUANG Guosheng.Department of Thoracic Surgery,Affiliated Hospital of Nanyang Medical School,Nanyang 473058,Henan;The efficacy of NP plus ENDOSTAR and chemotherapy in the treatment of non-small sell lung cancer[J];Henan Journal of Surgery;2007-06
6 Song Ziyan,Bian Baoxiang,Yang Chengxi(Department of Medical Oncology,the First People's Hospital of Lianyungang,Lianyungang 222002,China);Observation of Short-Term Effects of YH-16 Combined with GP Regimen for Non-Small Cell Lung Cancer[J];Journal of Basic and Clinical Oncology;2007-06
7 Cheng Peng1,Song Liang2(1.Department of Oncology,the First Affiliated Hospital of Nanyang Medical College;2.Department of Applied Mathematics,Nanyang Institute of Technology,Nanyang 473000,China);Clinical Observation of Endostar Combined with Local Hyperthermia and Transcatheter Arterial Chemoembolization(TACE) for Treatment of Advanced Hepatocellular Carcinoma[J];Journal of Basic and Clinical Oncology;2009-02
8 Wen Linchun,Zhang Longzhen(Department of Radiotherapy,the Affiliated Hospital of Xuzhou Medical College,Xuzhou 221000,China);The Observation of Short-Term Effects of YH-16 Combined with Concurrent Three Dimensional Conformal Radiotherapy on Locally Advanced Non-Small Cell Lung Cancer[J];Journal of Basic and Clinical Oncology;2009-03
9 WU Ying, ZHAO Min, YANG Li, LIU Jian, WEI Yu-quan,ZHAO Xia △. Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, China;Inhibition of Malignant Ascites with Endostatin Adenoviral Vector[J];Journal of Sichuan University (Medical Sciences Edition);2004-03
10 ZHOU Xingping QIN Rujuan LI Aiyang Department of Oncology,No 411 Hospital of PLA,Shanghai 200081,China;TU of the Joint Stereotactic Precision Radiotherapy for Cancer Patients with a Variety of Advanced Observation and Care[J];China Foreign Medical Treatment;2008-29
【Secondary References】
Chinese Journal Full-text Database 2 Hits
1 WU Yuan,TANG Jin-hai,SUN Wei-li.Department of Oncology,Jiangsu Cancer Hospital,Nanjing 210009,China;Progression of antiangiogenic therapy for breast cancer[J];Chinese Clinical Oncology;2010-05
2 DU Wei-li,WU Qing,WANG Li-wei.Department of Oncology,the First People's Hospital,Shanghai JiaoTong University,Shanghai 200080,China;Biomarkers of therapeutic effect evaluation and resistance to tumor antiangiogenic therapy[J];Chinese Clinical Oncology;2010-05
【Secondary Citations】
Chinese Journal Full-text Database 10 Hits
1 SHI Heling, XU Liyan, LIU Zhe. Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Hospital, Beijing 101149, P.R.China;Phase Ⅱ clinical trial of homemade human rh-endostatin in the treatment of patients with stage ⅢB--Ⅳ non-small cell lung cancer[J];Chinese Journal of Lung Cancer;2004-04
2 WANG Jinwan, SUN Yan, LIU Yongyu, YU Qitao, ZHANG Yiping, LI Kai, ZHU Yunzhong, ZHOU Qinghua, HOU Mei, GUAN Zhongzhen, LI Weilian, ZHUANG Wu, WANG Donglin, LIANG Houjie, QIN Fengzhan, LU Huishan, LIU Xiaoqing, SUN Hong, ZHANG Yanjun, WANG Jiejun, LUO Suxia, YANG Ruihe, TU Yuanrong, WANG Xiuwen, SONG Shuping, ZHOU Jingmin, YOU Lifen, WANG Jing, YAO Chen.  Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, P.R.China;Results of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients[J];Chinese Journal of Lung Cancer;2005-04
3 WANG Ying,SHI Dian peng,YU Jin ming,et al.Affiliated Hospital of Shandong Province Medicine Institute,Jinan 250062,China;Serum Endostatin Levels in Patients with Primary Lung Cancer[J];Journal of Qilu Oncology;2003-09
4 Su Lihong Zhou Ling Zhu Yan Li Fengqin (Institute of Materia,Shandong Academy of Medical Sciences,Jinan 250062);Recombinant Human Vascular Endostatin Inhibits Growth of Tumors in Nude Mice[J];Shandong Journal of Biomedical Engineering;2002-02
5 LIU Jiang-qiu, LI Zhong-yi, CHEN Lin-sheng, SUN Yi-hong, XU Lu, WANG Jun-yuan, LIU Wan-xing, XIA Jie-lai (Military Medical Institute of Shenyang Military Rigion, Shenyang 110034, Liaoning Province; Liaoning Research Institute of Satellite Biologicals; Ans;An experimental study on inhibiting growth and metastasis or mouse melanoma by engineering endostatin[J];Journal of Cellular and Molecular Immunology;2001-01
6 YANG Lin, WANG Jin-wan, SUN Yan, ZHU Yun-zhong, LIU Xia-qing, LI Wei-lian, DI Li-jun, LI Pei-wen, WANG You-liang, SONG Shu-ping, YAO Chen, YOU Li-fen. Department of Medical Oncology, Cancer Institue(Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China;Randomized phase Ⅱ trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer[J];Chinese Journal of Oncology;2006-02
7 Zhang Xiangru, Sun Yan, Kong Weihong, et al. Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021;Navelbine plus cisplatin combination therapy in the treatment of advanced non small cell lung cancer: a report of 42 cases[J];CHINESE JOURNAL OF ONCOLOGY;1998-01
8 LI Hui, ZHANG Peng, REN Xiu-bao, LIU Hong, HAO Xi-shan (Cancer Institute & Hospital, Tianjin Medical University, Tianjin 300060, China);Relation of the Amount of Circulating Endothelial Cells in Peripheral Blood and the Serum Level of VEGF in Tumor Patients[J];Chinese Journal of Cancer Biotherapy;2003-03
9 YANG Lin,WANG Jin-wan,TANG Zhong-ming,LIU Xiu-wen,HUANG Jing, LI Shu-ting,DONG Ying,ZHANG He-ping,XUE Lan,CHU Da-tong,SUN Yan (Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021, China ;Beijing Institute of Radiation Medicine , Beijing 100850, China );A phase Ⅰ clinical trial for recombinant human endostatin[J];Chinese New Drugs Journal;2004-06
10 YANG Lin, WANG Jin-wan, CUI Cheng-xu, HUANG Jing, ZHANG He-ping, LI Shu-ting, SUN Yan(Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China);Rh-endostatin(YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer:a multicenter phase Ⅱ trial[J];Chinese New Drugs Journal;2005-02
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved